Library
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia
Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
Celyad Announces Third Quarter 2018 Business Update
Celyad Announces Third Quarter 2018 Business Update
Celyad to Participate at Upcoming Healthcare Conferences
Celyad to Participate at Upcoming Healthcare Conferences
Differential effects of target ligands upon NKG2D CAR T cell activation
Differential effects of target ligands upon NKG2D CAR T cell activation
Generating Allogeneic CAR T cells without Gene Editing
Generating Allogeneic CAR T cells without Gene Editing
Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs
Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs
Functional screening of different anti-B7H6 CAR designs
Functional screening of different anti-B7H6 CAR designs
Overcoming target‐driven fratricide for CAR‐T cell therapy
Overcoming target‐driven fratricide for CAR‐T cell therapy
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
Celyad Presents Update on CYAD-01 Solid Tumor Clinical Program at the SITC 33rd Annual Meeting
The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo
The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo